June 6, 2017August 24, 2022
University of Michigan Researchers Identify 16 New Genetic Markers That Shed Light on Psoriasis
News
University of Michigan researchers have shed more light on the genetic landscape behind the intricate mechanisms of psoriasis. The 16 ... Read more
June 1, 2017
OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany
News
One World Cannabis Pharmaceutical Research (OWCP) and mediq Innovation Experts have partnered to introduce OWCP’s cannabinoid-based topical psoriasis cream in Germany. ... Read more
May 30, 2017May 30, 2017
FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis
News
The U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for Sun Pharmaceutical’s lead investigational drug tildrakizumab ... Read more
May 25, 2017May 25, 2017
Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis
News
Janssen announced two new Phase 3 clinical trials for psoriasis for its investigational drug guselkumab. The company intends to explore ... Read more
May 23, 2017
Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13, Clinical Trial Suggests
News
Patients taking Remicade (infliximab) can safely switch to treatment with biosimilar CT-P13, sold as Pfizer’s Inflectra and Celltrion Healthcare’s Remsima, according to ... Read more
May 16, 2017May 16, 2017
Cannabinoids Have Potential to Treat Skin Conditions Like Psoriasis, Review Shows
News
Compounds extracted from the cannabis plant (cannabinoids) have therapeutic proprieties that could be used to treat several skin conditions, including psoriasis, ... Read more
May 11, 2017
Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target
News
An already started Phase 2b clinical trial of Prurisol as a treatment for moderate-to-severe chronic plaque psoriasis has recruited more than 70 ... Read more
May 9, 2017
Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease
News
Pfizer’s rheumatoid arthritis drug Xeljanz (tofacitinib) was effective against nail psoriasis in patients with plaque disease, according to data from ... Read more
May 4, 2017May 4, 2017
FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients
News
The U.S. Food and Drug Administration (FDA) will review Pfizer’s medication Xeljanz (tofacitinib citrate) 5 mg twice daily, to treat adults with ... Read more
May 2, 2017
Cimzia and Cosentyx Approved to Treat Active Psoriatic Arthritis in England and Wales
News
The U.K.’s National Institute for Health and Care Excellence (NICE) has approved the use of Cimzia (certolizumab pegol) and Cosentyx (secukinumab), ... Read more
April 27, 2017April 27, 2017
Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month
News
Siliq (brodalumab) injection, recently approved to treat adults with severe plaque psoriasis, will be available in the U.S. at a ... Read more
April 20, 2017April 20, 2017
XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata
News
XTRAC targeted-light therapy safely treats skin lesions in psoriasis patients without the serious side effects linked to Humira and other conventional psoriasis drugs, ... Read more

March 21, 2017March 21, 2017

Results from Second Phase 3 Trial Show Effectiveness, Superiority of Guselkumab for Plaque Psoriasis

News

New findings from two pivotal Phase 3 studies evaluating the effectiveness and safety of Janssen’ guselkumab for the treatment of moderate to severe plaque psoriasis demonstrated the drug’s superiority compared to ... Read more

March 16, 2017March 16, 2017

MetrioPharm Reports Positive Phase 2a Trial Results of MP1032 for Plaque Psoriasis

News

MetrioPharm reported positive results from a Phase 2a clinical trial evaluating its drug candidate MP1032 in patients with moderate to severe plaque psoriasis, and now plans to conduct a Phase ... Read more

March 14, 2017

Psoriatic Arthritis Patients Often Disagree with Rheumatologists on Disease Activity, Study Suggests

News

Psoriatic arthritis patients’ perception of their disease activity is often different from their rheumatologists, according to the results of a new analysis. The study, “Misalignment between physicians and patient satisfaction with ... Read more

March 9, 2017

Cosentyx Effective For Re-Treating Plaque Psoriasis Patients, Novartis Analysis Shows

News

Swiss drugmaker Novartis says re-treatment with Cosentyx (secukinumab) for moderate to severe plaque psoriasis helps patients rapidly regain clear or almost clear skin (Psoriasis Area Severity Index, PASI 100 or 90) following relapse during a treatment ... Read more

March 7, 2017

Otezla Found Superior to Placebo in Treating Moderate Plaque Psoriasis, Celgene Reports

News

Celgene reported positive results from its Phase 4 UNVEIL clinical trial that evaluated Otezla (apremilast) in patients with moderate plaque psoriasis with a body surface area (BSA) of 5-10%. The results were ... Read more

March 2, 2017

Skin’s Immune Response Thrown Off Balance in Psoriasis, Study Finds

News

Researchers at Karolinska Institute in Sweden showed how the local immune response of the skin is thrown out of balance in inflammatory skin diseases such as psoriasis and vitiligo. ... Read more

February 28, 2017

Depression Increases Risk of Psoriatic Arthritis in Psoriasis Patients, Study Shows

News

Psoriasis patients who developed depression had a 37 percent increased risk of developing psoriatic arthritis, according to researchers at the University of Calgary in Canada. The study, “Depression Is Associated with ... Read more

February 23, 2017

Soligenix Gets European Union Patent for Synthetic Hypericin as Psoriasis Therapy

News

The European Union has granted Soligenix a patent for its proprietary formulation of synthetic hypericin (SGX301) as a treatment for psoriasis. Synthetic hypericin, the active ingredient in SGX301, is a photosensitizer ... Read more

February 21, 2017

Biologic Agents May Up Risk of Squamous Cell Carcinoma Among Psoriasis Patients, Study Suggests

News

An increased incidence of cutaneous squamous cell carcinoma was found among psoriasis patients who were treated with biologic agents. A study with those results, “Malignancy rates in a large cohort ... Read more

February 16, 2017April 24, 2017

Biologic Psoriasis Treatment, Siliq, Approved by FDA with Strong Warning of Possible Suicide Risk

News

A biologic designed for the treatment of inflammatory diseases, Siliq (brodalumab), has been approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate-to-severe plaque psoriasis. Due to ... Read more

University of Michigan Researchers Identify 16 New Genetic Markers That Shed Light on Psoriasis

OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany

FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis

Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis

Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13, Clinical Trial Suggests

Cannabinoids Have Potential to Treat Skin Conditions Like Psoriasis, Review Shows

Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target

Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease

FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients

Cimzia and Cosentyx Approved to Treat Active Psoriatic Arthritis in England and Wales

Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month

XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata